MX360236B - Uso de marcadores en el diagnostico y tratamiento de cancer de prostata. - Google Patents
Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.Info
- Publication number
- MX360236B MX360236B MX2015000008A MX2015000008A MX360236B MX 360236 B MX360236 B MX 360236B MX 2015000008 A MX2015000008 A MX 2015000008A MX 2015000008 A MX2015000008 A MX 2015000008A MX 360236 B MX360236 B MX 360236B
- Authority
- MX
- Mexico
- Prior art keywords
- diagnosis
- keratin
- prostate cancer
- markers
- treatment
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 2
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000013366 Filamin Human genes 0.000 abstract 1
- 108060002900 Filamin Proteins 0.000 abstract 1
- 102100040443 Keratin, type I cytoskeletal 15 Human genes 0.000 abstract 1
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 abstract 1
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 abstract 1
- 102100025758 Keratin, type II cytoskeletal 4 Human genes 0.000 abstract 1
- 102100023974 Keratin, type II cytoskeletal 7 Human genes 0.000 abstract 1
- 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 abstract 1
- 108010066330 Keratin-15 Proteins 0.000 abstract 1
- 108010066327 Keratin-18 Proteins 0.000 abstract 1
- 108010066302 Keratin-19 Proteins 0.000 abstract 1
- 108010070921 Keratin-4 Proteins 0.000 abstract 1
- 108010070507 Keratin-7 Proteins 0.000 abstract 1
- 108010070511 Keratin-8 Proteins 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- -1 tubulin-beta 3 Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4742—Keratin; Cytokeratin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261665201P | 2012-06-27 | 2012-06-27 | |
| US201261672090P | 2012-07-16 | 2012-07-16 | |
| US201261673094P | 2012-07-18 | 2012-07-18 | |
| US201261702523P | 2012-09-18 | 2012-09-18 | |
| US201261718064P | 2012-10-24 | 2012-10-24 | |
| US201261718080P | 2012-10-24 | 2012-10-24 | |
| US201261718081P | 2012-10-24 | 2012-10-24 | |
| PCT/US2013/048373 WO2014004931A1 (en) | 2012-06-27 | 2013-06-27 | Use of markers in the diagnosis and treatment of prostate cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015000008A MX2015000008A (es) | 2015-04-10 |
| MX360236B true MX360236B (es) | 2018-10-26 |
Family
ID=49783880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015000008A MX360236B (es) | 2012-06-27 | 2013-06-27 | Uso de marcadores en el diagnostico y tratamiento de cancer de prostata. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20140038838A1 (enExample) |
| EP (1) | EP2867375B1 (enExample) |
| JP (2) | JP6352909B2 (enExample) |
| KR (1) | KR20150023904A (enExample) |
| CN (1) | CN104583422A (enExample) |
| AU (1) | AU2013284448B2 (enExample) |
| BR (1) | BR112014032728A2 (enExample) |
| CA (1) | CA2877721A1 (enExample) |
| EA (1) | EA201492284A1 (enExample) |
| ES (1) | ES2720763T3 (enExample) |
| IL (1) | IL236482A0 (enExample) |
| MX (1) | MX360236B (enExample) |
| NZ (1) | NZ703411A (enExample) |
| SG (1) | SG11201408651TA (enExample) |
| WO (1) | WO2014004931A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3312749B1 (en) | 2012-03-05 | 2024-05-01 | OY Arctic Partners AB | Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume |
| CN106061998B (zh) * | 2014-02-05 | 2020-12-11 | 弗吉瑞必欧诊断股份公司 | 用于检测恶性赘生性疾病的组合物和方法 |
| US12326453B2 (en) | 2014-03-28 | 2025-06-10 | Opko Diagnostics, Llc | Compositions and methods for active surveillance of prostate cancer |
| FI3123381T3 (fi) | 2014-03-28 | 2023-11-27 | Opko Diagnostics Llc | Eturauhassyövän diagnosointiin liittyviä koostumuksia ja menetelmiä |
| SG11201704660YA (en) * | 2014-12-08 | 2017-07-28 | Berg Llc | Use of markers including filamin a in the diagnosis and treatment of prostate cancer |
| CA2979559A1 (en) | 2015-03-27 | 2016-10-06 | Opko Diagnostics, Llc | Prostate antigen standards and uses thereof |
| WO2017210562A1 (en) * | 2016-06-03 | 2017-12-07 | Etubics Corporation | Compositions and methods for tumor vaccination using prostate cancer-associated antigens |
| EP3490677A4 (en) * | 2016-07-07 | 2020-05-13 | Berg LLC | LIPID, PROTEIN AND METABOLIC MARKERS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER |
| WO2018189292A1 (en) * | 2017-04-13 | 2018-10-18 | Institut National De La Sante Et De La Recherche Medicale | Biomarkers of castration-resistant prostatic cells |
| KR102405789B1 (ko) * | 2018-08-24 | 2022-06-07 | 고려대학교 세종산학협력단 | 키누레닌 경로 대사체를 포함하는 전립선암 진단용 바이오마커 조성물 |
| CN109608536B (zh) * | 2018-12-12 | 2020-09-15 | 深圳市龙华区人民医院 | 基于前列腺癌干细胞标志物cd44的抗原表位多肽cd44-p3及其应用 |
| CN109608537B (zh) * | 2018-12-12 | 2020-09-15 | 深圳市龙华区人民医院 | 基于前列腺癌干细胞标志物cd44的抗原表位多肽cd44-p2及其应用 |
| KR102497196B1 (ko) * | 2020-09-08 | 2023-02-07 | (주)유로테크 | 전립선암 진단 점수 계산 방법 및 그 용도 |
| CN114134223B (zh) * | 2021-12-02 | 2022-10-11 | 青岛市中心血站 | 一种用于丙型肝炎病毒相关肝纤维化的血液检测试剂盒 |
| CN114460297A (zh) * | 2022-01-17 | 2022-05-10 | 珠海中科先进技术研究院有限公司 | 一种用于检测血液中循环前列腺上皮细胞的免疫荧光试剂盒及其使用方法 |
Family Cites Families (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3942999C2 (de) | 1989-12-27 | 1997-12-18 | Progen Biotechnik Gmbh | Verfahren zum Nachweis von malignen Erkrankungen |
| DE4208422A1 (de) | 1992-03-16 | 1993-09-30 | Boehringer Mannheim Gmbh | Verfahren zum Nachweis von Mikrometastasen ekto- oder entodermaler Tumoren |
| ES2347854T5 (es) | 1996-03-26 | 2014-07-24 | Michael S. Kopreski | Método que permite el uso de RNA extracelular extraído de plasma o suero para detectar, monitorizar o evaluar un cáncer |
| US6107103A (en) * | 1996-10-15 | 2000-08-22 | Procyon Bropharma Inc. | Assay for PSP94 protein |
| US6207380B1 (en) | 1997-09-15 | 2001-03-27 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the urinary tract |
| US7361336B1 (en) | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
| DE69911226D1 (de) | 1998-10-22 | 2003-10-16 | Curagen Corp | Prädiktive und therapeutische für nierenerkrankungen gene und proteine |
| WO2000040749A2 (en) | 1999-01-06 | 2000-07-13 | Genenews Inc. | Method for the detection of gene transcripts in blood and uses thereof |
| US8410248B2 (en) | 1999-03-12 | 2013-04-02 | Human Genome Sciences Inc. | HWBAO62 polypeptides |
| US7368527B2 (en) | 1999-03-12 | 2008-05-06 | Human Genome Sciences, Inc. | HADDE71 polypeptides |
| US6844153B2 (en) | 2000-03-27 | 2005-01-18 | Thomas Jefferson University | Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
| EP1309679A2 (en) | 2000-08-16 | 2003-05-14 | Chiron Corporation | Human genes and gene expression products |
| WO2002060317A2 (en) | 2001-01-30 | 2002-08-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of pancreatic cancer |
| DE60232059D1 (de) | 2001-03-01 | 2009-06-04 | Epigenomics Ag | Verfahren zur entwicklung von gensätzen zu diagnostischen und therapeutischen zwecken auf grundlage des expressions- und methylierungsstatus der gene |
| EP2261368A1 (en) | 2002-03-13 | 2010-12-15 | Genomic Health, Inc. | Gene expression profiling in biopsied tumor tissues |
| US20040029151A1 (en) | 2002-04-09 | 2004-02-12 | Affymetrix, Inc. | Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer |
| EP1510587B1 (en) | 2002-05-21 | 2011-07-13 | Sysmex Corporation | Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers |
| EP2500438A3 (en) | 2002-09-25 | 2012-11-28 | Genentech, Inc. | Novel compositions and methods for the treatment of psoriasis |
| US20050259483A1 (en) | 2002-09-30 | 2005-11-24 | Oncotherapy Science, Inc. | Genes and polypeptides relating to prostate cancers |
| US20040109863A1 (en) * | 2002-12-04 | 2004-06-10 | Peter Emtage | Methods of therapy and diagnosis using targeting of cells that express Ly-9 |
| DE10259703A1 (de) | 2002-12-19 | 2004-07-08 | Ivonex Gmbh | Trennungsverfahren |
| EP2474630B1 (en) | 2002-12-20 | 2016-04-27 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
| WO2004076614A2 (de) * | 2003-02-27 | 2004-09-10 | Bernd Hinzmann | Humane nukleinsäuresequenzen aus prostatakarzinomen |
| EP1604014A4 (en) | 2003-03-20 | 2008-03-26 | Dana Farber Cancer Inst Inc | GENE EXPRESSION IN BREAST CANCER |
| EP1631689A2 (en) | 2003-05-28 | 2006-03-08 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| KR20060031809A (ko) | 2003-06-09 | 2006-04-13 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 암 치료 및 진단용 조성물 및 방법 |
| WO2005007830A2 (en) | 2003-07-14 | 2005-01-27 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
| CA2533803A1 (en) | 2003-07-29 | 2005-02-10 | Bristol-Myers Squibb Company | Biomarkers of cyclin-dependent kinase modulation |
| EP1522594A3 (en) | 2003-10-06 | 2005-06-22 | Bayer HealthCare AG | Methods and kits for investigating cancer |
| ITPD20030264A1 (it) | 2003-10-30 | 2005-04-30 | Xeptagen Spa | Metodo di diagnosi altamente specifico per neoplasie |
| CN1743849A (zh) | 2004-09-03 | 2006-03-08 | 上海透景生命科技有限公司 | 一种多肿瘤标志物并行检测的方法及试剂盒 |
| US20060057127A1 (en) | 2004-09-10 | 2006-03-16 | Pocheng Liu | Cytokine-expressing cellular vaccines for treatment of prostate cancer |
| US20060063214A1 (en) | 2004-09-17 | 2006-03-23 | Ozge Alper | Methods and compositions for diagnosing neoplastic disease |
| AU2005300688B2 (en) | 2004-11-03 | 2012-02-02 | Almac Diagnostics Limited | Transcriptome microarray technology and methods of using the same |
| WO2006101925A2 (en) | 2005-03-16 | 2006-09-28 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| US8383357B2 (en) | 2005-03-16 | 2013-02-26 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| US7608413B1 (en) | 2005-03-25 | 2009-10-27 | Celera Corporation | Kidney disease targets and uses thereof |
| US9234897B2 (en) | 2005-03-31 | 2016-01-12 | Two Cells Co., Ltd | Method for distinguishing mesenchymal stem cell using molecular marker and use thereof |
| EP1910564A1 (en) | 2005-05-13 | 2008-04-16 | Duke University | Gene expression signatures for oncogenic pathway deregulation |
| US8609345B2 (en) * | 2005-05-25 | 2013-12-17 | Expression Pathology Incorporated | Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations |
| JP5166250B2 (ja) | 2005-05-25 | 2013-03-21 | エクスプレッション、パソロジー、インコーポレイテッド | 組織病理学的に処理した生物学的試料からのプロテオームの適用範囲を増加させるための、液体組織標品を用いたマルチプレックス方法 |
| US20070099209A1 (en) | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| WO2006138275A2 (en) * | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| EP1734118A1 (en) | 2005-06-15 | 2006-12-20 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Identification of JAK/STAT pathway modulating genes by genome wide RNAi screening |
| US7842466B1 (en) | 2005-09-16 | 2010-11-30 | Celera Corporation | Colon disease targets and uses thereof |
| CA2625403A1 (en) | 2005-10-17 | 2007-04-26 | Institute For System Biology | Tissue-and serum-derived glycoproteins and methods of their use |
| US20070220621A1 (en) | 2005-10-31 | 2007-09-20 | Clarke Michael F | Genetic characterization and prognostic significance of cancer stem cells in cancer |
| US20070122856A1 (en) | 2005-11-10 | 2007-05-31 | Aurelium Biopharma Inc. | Tissue diagnostics for ovarian cancer |
| EP1963860A1 (en) * | 2005-12-19 | 2008-09-03 | University of Hull | Cancer screening test |
| US20070231822A1 (en) | 2006-02-28 | 2007-10-04 | Michael Mitas | Methods for the detection and treatment of cancer |
| JP4968577B2 (ja) | 2006-04-11 | 2012-07-04 | エフ．ホフマン−ラ ロシュ アーゲー | サイトケラチン１９（ＣＫ１９）ｍＲＮＡの迅速測定法、並びにそのためのプライマー及びプローブ |
| US20080003624A1 (en) | 2006-06-13 | 2008-01-03 | Sysmex Corporation | Cancer metastasis determination method |
| WO2008013989A2 (en) | 2006-07-27 | 2008-01-31 | Cell Genesys, Inc. | Methods and compositions for identifying a cellular immune response against prostate cancer |
| JP5244103B2 (ja) | 2006-08-09 | 2013-07-24 | ホームステッド クリニカル コーポレイション | 器官特異的蛋白質およびその使用方法 |
| US8642349B1 (en) | 2006-08-11 | 2014-02-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Artificial neural network proteomic tumor classification |
| US8748108B2 (en) | 2006-09-05 | 2014-06-10 | Abbvie Inc. | Biomarkers for identifying patient classes |
| ES2375453T3 (es) | 2006-09-07 | 2012-03-01 | Universitätsklinikum Hamburg-Eppendorf | Método para la detección de células epiteliales cancerosas utilizando citoqueratinas liberadas como marcadores para dichas células. |
| RU2473555C2 (ru) | 2006-12-19 | 2013-01-27 | ДжинГоу, Инк. | Новые способы функционального анализа большого количества экспериментальных данных и групп генов, идентифицированных из указанных данных |
| JP5247729B2 (ja) * | 2007-03-02 | 2013-07-24 | セルル ゲネスイス，インコーポレイテッド | 前立腺癌、又は前立腺癌に対する体液性免疫応答を同定するための方法、及び組成物 |
| US20090081659A1 (en) | 2007-03-07 | 2009-03-26 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
| WO2008121307A2 (en) * | 2007-03-28 | 2008-10-09 | Cell Genesys, Inc. | Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer |
| US8492328B2 (en) | 2007-05-17 | 2013-07-23 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
| US20090221004A1 (en) | 2007-06-01 | 2009-09-03 | Anita Lim Hong | Caspase-cleavage anti-keratin antibodies for detection of apoptosis |
| WO2009038754A2 (en) | 2007-09-19 | 2009-03-26 | The Research Foundation Of State University Of New York | Gene expression signatures in enriched tumor cell samples |
| CA2694356A1 (en) | 2007-10-03 | 2009-04-09 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| US20090105167A1 (en) | 2007-10-19 | 2009-04-23 | Duke University | Predicting responsiveness to cancer therapeutics |
| BRPI0820793A2 (pt) | 2007-12-10 | 2015-06-16 | Hoffmann La Roche | Seprase como marcador de câncer |
| EP2604704B1 (en) | 2008-02-01 | 2018-10-03 | The General Hospital Corporation | Use of microvesicles in diagnosis and prognosis of brain tumor |
| US8008032B2 (en) | 2008-02-25 | 2011-08-30 | Cellective Dx Corporation | Tagged ligands for enrichment of rare analytes from a mixed sample |
| MX2011000451A (es) | 2008-07-16 | 2011-10-12 | Dana Farber Cancer Inst Inc | Distintivos y determinantes asociados con cancer de próstata y métodos para utilizarlos. |
| WO2010011642A2 (en) | 2008-07-21 | 2010-01-28 | The Trustees Of The University Of Pennsylvania | Methods and compositions using splicing regulatory proteins involved in tumor suppression |
| EP2177615A1 (en) | 2008-10-10 | 2010-04-21 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases |
| IT1391619B1 (it) | 2008-11-04 | 2012-01-11 | Silicon Biosystems Spa | Metodo per l'individuazione, selezione e analisi di cellule tumorali |
| EP2356461B1 (en) | 2008-11-12 | 2013-10-09 | Roche Diagnostics GmbH | Pacap as a marker for cancer |
| WO2010065940A1 (en) | 2008-12-04 | 2010-06-10 | The Regents Of The University Of California | Materials and methods for determining diagnosis and prognosis of prostate cancer |
| WO2010072383A1 (en) | 2008-12-22 | 2010-07-01 | 7Roche Diagnostics Gmbh | Armet as a marker for cancer |
| JP2012519170A (ja) | 2009-02-26 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法 |
| JP2012100536A (ja) | 2009-03-02 | 2012-05-31 | Genescience Co Ltd | 血液試料に含まれる単核球細胞を用いた癌関連遺伝子の発現解析による癌の遺伝子検査方法 |
| WO2010099918A1 (en) | 2009-03-06 | 2010-09-10 | Klaus Tschira Stiftung Ggmbh | Pharmaceutical composition and method for identifying a cancerous and/or an inflammatory disease in a patient |
| US20120100538A1 (en) | 2009-03-24 | 2012-04-26 | Biocept, Inc. | Devices and methods of cell capture and analysis |
| US10815517B2 (en) | 2009-04-28 | 2020-10-27 | Roche Diagnostics Operations, Inc. | Use of DPPIV/seprase as a marker for cancer |
| EP2484762A4 (en) * | 2009-10-02 | 2013-03-27 | Univ Kurume | METHOD FOR PREDICTING THE THERAPEUTIC EFFECT OF IMMUNOTHERAPY ON A CANCER PATIENTS AND / OR FORECASTING AFTER IMMUNOTHERAPY AND THE KIT AND KIT THEREFOR |
| WO2011053837A1 (en) | 2009-10-29 | 2011-05-05 | King Kutter, Inc. | Stump cutter |
| EP2335838B1 (en) | 2009-12-18 | 2012-09-26 | Deutsche Post AG | Sorting system and method using a portable device |
| US20130095503A1 (en) | 2010-01-05 | 2013-04-18 | University Of Cincinnati | Serum spla2-iia as diagnosis marker for prostate and lung cancer |
| US20110177525A1 (en) | 2010-01-19 | 2011-07-21 | Predictive Biosciences, Inc. | Antibodies and methods of diagnosing diseases |
| CA2795776A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers for disease |
| US8664472B2 (en) | 2010-04-28 | 2014-03-04 | Sesaco Corporation | Pygmy sesame plants for mechanical harvesting |
| EP2390665A1 (en) * | 2010-05-27 | 2011-11-30 | Atlas Antibodies AB | Prostate cancer biomarkers |
| US8557777B2 (en) | 2010-07-09 | 2013-10-15 | The Board Of Trustees Of The University Of Illinois | Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides |
| WO2012006634A2 (en) | 2010-07-09 | 2012-01-12 | The Board Of Trustees Of The University Of Illiniois | Prostate specific antigen (psa) peptide therapy |
| CA2807811A1 (en) * | 2010-07-28 | 2012-02-02 | Metabolon Inc. | Biomarkers for prostate cancer and methods using the same |
| EP2606165B1 (en) * | 2010-08-16 | 2016-10-12 | Sinai Health System | Markers of the male urogenital tract |
| WO2012024543A1 (en) * | 2010-08-18 | 2012-02-23 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
| US20140045915A1 (en) | 2010-08-31 | 2014-02-13 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
| WO2012031374A1 (zh) | 2010-09-09 | 2012-03-15 | 北京同为时代生物技术有限公司 | 用于诊断上皮源性癌症的血液标志物及其单克隆抗体 |
| KR20140034124A (ko) | 2010-12-06 | 2014-03-19 | 티에이치디 에스.피.에이. | 암종의 진단방법 및 그의 용도 |
| AU2011349101A1 (en) | 2010-12-24 | 2013-05-02 | Map Diagnostics Pty Ltd | Selective reaction monitoring (SRM) derived protein profiles for cancer and other pathologic entities |
| WO2012101283A1 (en) | 2011-01-28 | 2012-08-02 | Biosystems International Sas | Combinatorial biomarkers for clinical applications in lung cancer patient management |
| WO2012116248A1 (en) | 2011-02-24 | 2012-08-30 | Massachusetts Institute Of Technology | ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER |
| KR101320633B1 (ko) | 2011-05-25 | 2013-10-30 | 엠앤디 (주) | 실시간 중합반응을 이용한 암의 진단을 위한 정보제공방법 및 이를 위한 암 진단용 키트 |
| WO2012135397A2 (en) | 2011-03-29 | 2012-10-04 | Lisanti Michael P | Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome |
| WO2012174256A2 (en) | 2011-06-17 | 2012-12-20 | The Regents Of The University Of Michigan | Dna methylation profiles in cancer |
| ES2571380T3 (es) | 2011-07-26 | 2016-05-25 | Univ Salamanca | Método para la detección de infiltración cancerosa en el sistema nervioso central |
| KR20140067001A (ko) | 2011-08-08 | 2014-06-03 | 카리스 라이프 사이언스 룩셈부르크 홀딩스, 에스.에이.알.엘. | 생물지표 조성물 및 방법 |
| CA2848162C (en) | 2011-09-12 | 2023-03-14 | Creatics Llc | Non-invasive methods of detecting target molecules |
| WO2013134786A2 (en) | 2012-03-09 | 2013-09-12 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Biomarker compositions and methods |
| EP2831104B1 (en) | 2012-03-29 | 2021-04-21 | Biogen MA Inc. | Biomarkers for use in integrin therapy applications |
| US20130317083A1 (en) | 2012-05-04 | 2013-11-28 | Thomas Jefferson University | Non-coding transcripts for determination of cellular states |
| TWI468519B (zh) | 2012-09-05 | 2015-01-11 | Univ China Medical | Methods of detecting squamous cell carcinoma in vitro |
| US20150226744A1 (en) | 2012-09-17 | 2015-08-13 | Ait Austrian Institute Of Technology Gmbh | Colon Cancer Diagnostic Method and Means |
| US9201061B2 (en) | 2013-02-26 | 2015-12-01 | Industry-University Cooperation Foundation Hanyang University | KRT19 stabilizing HER2 and use thereof |
| CA2902841A1 (en) | 2013-03-13 | 2014-10-02 | Creatics Llc | Methods and compositions for detecting pancreatic cancer |
| SE538211C2 (sv) | 2013-04-05 | 2016-04-05 | Idl Biotech Ab | Metod för detektering av cytokeratin 8, 18 och/eller 19 och/eller lösliga fragment därav |
| US20150079590A1 (en) | 2013-09-18 | 2015-03-19 | Beth Israel Deaconess Medical Center, Inc. | Characterization and analysis of the composition and dynamics of the mammalian riboproteome |
| WO2015042465A1 (en) | 2013-09-20 | 2015-03-26 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain |
-
2013
- 2013-06-27 KR KR1020157002289A patent/KR20150023904A/ko not_active Ceased
- 2013-06-27 NZ NZ703411A patent/NZ703411A/en not_active IP Right Cessation
- 2013-06-27 WO PCT/US2013/048373 patent/WO2014004931A1/en not_active Ceased
- 2013-06-27 BR BR112014032728A patent/BR112014032728A2/pt not_active IP Right Cessation
- 2013-06-27 EA EA201492284A patent/EA201492284A1/ru unknown
- 2013-06-27 CA CA2877721A patent/CA2877721A1/en not_active Abandoned
- 2013-06-27 EP EP13809780.3A patent/EP2867375B1/en active Active
- 2013-06-27 AU AU2013284448A patent/AU2013284448B2/en not_active Ceased
- 2013-06-27 JP JP2015520541A patent/JP6352909B2/ja not_active Expired - Fee Related
- 2013-06-27 ES ES13809780T patent/ES2720763T3/es active Active
- 2013-06-27 US US13/929,723 patent/US20140038838A1/en not_active Abandoned
- 2013-06-27 MX MX2015000008A patent/MX360236B/es active IP Right Grant
- 2013-06-27 SG SG11201408651TA patent/SG11201408651TA/en unknown
- 2013-06-27 CN CN201380045178.1A patent/CN104583422A/zh active Pending
-
2014
- 2014-12-25 IL IL236482A patent/IL236482A0/en unknown
-
2016
- 2016-03-02 US US15/059,238 patent/US9797905B2/en active Active
-
2017
- 2017-09-15 US US15/706,105 patent/US20180031563A1/en not_active Abandoned
-
2018
- 2018-06-07 JP JP2018109092A patent/JP6581247B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| IL236482A0 (en) | 2015-02-26 |
| JP2018163164A (ja) | 2018-10-18 |
| CA2877721A1 (en) | 2014-01-03 |
| EP2867375A1 (en) | 2015-05-06 |
| US9797905B2 (en) | 2017-10-24 |
| EP2867375A4 (en) | 2016-06-01 |
| KR20150023904A (ko) | 2015-03-05 |
| MX2015000008A (es) | 2015-04-10 |
| JP6352909B2 (ja) | 2018-07-04 |
| HK1209792A1 (en) | 2016-04-08 |
| AU2013284448A1 (en) | 2015-01-22 |
| JP6581247B2 (ja) | 2019-09-25 |
| EA201492284A1 (ru) | 2015-11-30 |
| AU2013284448B2 (en) | 2019-04-18 |
| US20160178632A1 (en) | 2016-06-23 |
| JP2015523569A (ja) | 2015-08-13 |
| ES2720763T3 (es) | 2019-07-24 |
| WO2014004931A1 (en) | 2014-01-03 |
| NZ703411A (en) | 2017-09-29 |
| BR112014032728A2 (pt) | 2017-11-28 |
| EP2867375B1 (en) | 2019-02-27 |
| US20140038838A1 (en) | 2014-02-06 |
| US20180031563A1 (en) | 2018-02-01 |
| CN104583422A (zh) | 2015-04-29 |
| SG11201408651TA (en) | 2015-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX360236B (es) | Uso de marcadores en el diagnostico y tratamiento de cancer de prostata. | |
| MY176706A (en) | Biomarkers and methods of treating pd-1 and pd-l1 related conditions | |
| EP4242329A3 (en) | Use of markers including filamin a in the diagnosis and treatment of prostate cancer | |
| AU2011260390A8 (en) | Means and methods for diagnosing pancreatic cancer in a subject | |
| MX2014005800A (es) | Mutaciones del receptor notch humano y su uso. | |
| NZ601065A (en) | Wnt antagonists and methods of treatment and screening | |
| CY1123716T1 (el) | Αντι-ανδρογονα για τη θεραπεια μη μεταστατικου ευνουχοαντοχου καρκινου του προστατη | |
| HK1202313A1 (en) | Methods and compositions for the treatment and diagnosis of bladder cancer | |
| SG10201901076WA (en) | Methods of treating alzheimer's disease | |
| GB2538178A (en) | Viscosifier polymer for treatment of a subterranean formation | |
| WO2014150751A3 (en) | Biomarkers associated with brm inhibition | |
| WO2010017515A3 (en) | Breast cancer specific markers and methods of use | |
| PH12014501164A1 (en) | Anti-cd98 antibodies and methods of use thereof | |
| MX2015007185A (es) | Uso de eribulina en el tratamiento de cancer de pecho. | |
| PH12014500063A1 (en) | Methods and nucleic acids for determining the prognosis of a cancer subject | |
| EP3486657A3 (en) | Means and methods for diagnosing pancreatic cancer in a subject | |
| PH12016500302A1 (en) | Compositions and method for treating complement-associated conditions | |
| EP4513187A3 (en) | Methods of detecting prostate cancer | |
| WO2014205266A3 (en) | Compositions and methods for detecting and treating glioblastoma | |
| NZ708654A (en) | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors | |
| WO2013106747A3 (en) | Methods and compositions for the treatment and diagnosis of thyroid cancer | |
| WO2014043633A8 (en) | Use of e-cadherin and vimentin for selection of treatment responsive patients | |
| MA40636A (fr) | Procédés pour détecter le cancer de la prostate | |
| WO2013081645A3 (en) | Erbb3 mutations in cancer | |
| WO2015013233A3 (en) | Methods and compositions for the treatment and diagnosis of bladder cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |